Absci CORP 10-Q quarterly reports

Absci Corporation's Q2 2026 filing reveals a widening net loss and increased R&D expenses, though positive interim data for its lead candidate ABS-201 offers a glimmer of progress.

Absci Corporation reports increased net losses and decreased partner revenue in Q3 2025, while advancing its AI drug creation platform and seeking a partner for its lead candidate ABS-101.

Absci Corporation reported increased net losses and decreased revenue for Q2 2025, driven by higher research and development expenses, but bolstered its liquidity with over $60 million in post-period capital raises.

Absci Corporation's Q1 2025 results show increased revenue from partner programs and ongoing clinical development of ABS-101 for Inflammatory Bowel Disease.

Absci Corporation's Q3 2024 results show increased revenue and a reduced net loss compared to the previous quarter, alongside advancements in their AI-driven drug creation platform.

Absci Corporation's Q2 2024 results show a decrease in technology development revenue compared to the same period last year, while the company continues to invest in research and development.

Absci Corporation reported a net loss of $22.0 million for the first quarter of 2024, with technology development revenue of $0.9 million and a focus on advancing its integrated drug creation platform and internal pipeline.